Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
33161592
PubMed Central
PMC8247412
DOI
10.1111/bjh.17210
Knihovny.cz E-zdroje
- Klíčová slova
- ALL, AML, acute leukaemia, flow cytometry, immunophenotyping, myeloperoxidase,
- MeSH
- akutní nemoc MeSH
- imunofenotypizace normy MeSH
- leukemie * diagnóza enzymologie imunologie MeSH
- lidé MeSH
- nádorové proteiny * krev imunologie MeSH
- peroxidasa * krev imunologie MeSH
- průtoková cytometrie normy MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- MPO protein, human MeSH Prohlížeč
- nádorové proteiny * MeSH
- peroxidasa * MeSH
Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
Cancer Research Center Salamanca Spain
Centro de Investigaciόn Biomédicaen Red de Cáncer Instituto Carlos 3 Madrid Spain
Department of Hematology Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands
Department of Immunology Leiden University Medical Center Leiden The Netherlands
Department of Pediatric Hematology and Oncology Zabrze Medical University of Silesia Katowice Poland
Dutch Childhood Oncology Group Utrecht the Netherlands
Institute for Laboratory Medicine Kantonsspital Aarau AG Aarau Switzerland
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Zobrazit více v PubMed
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. PubMed
Olsen RJ, Chang CC, Herrick JL, Zu Y, Ehsan A. Acute leukemia immunohistochemistry: a systematic diagnostic approach. Arch Pathol Lab Med. 2008;132:462–75. PubMed
Kappelmayer J, Gratama JW, Karászi E, Menéndez P, Ciudad J, Rivas R, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods. 2000;242:53–65. PubMed
Ahuja A, Tyagi S, Seth T, Pati HP, Gahlot G, Tripathi P, et al. Comparison of immunohistochemistry, cytochemistry, and flow cytometry in AML for myeloperoxidase detection. Indian J Hematol Blood Transfus. 2018;34:233–9. PubMed PMC
Reilly JT, Barnett D. UK NEQAS for leucocyte immunophenotyping: the first 10 years. J Clin Pathol. 2001;54:508–11. PubMed PMC
Kalina T, Flores‐Montero J, van der Velden VHJ, Martin‐Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010. PubMed PMC
van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores‐Montero J, et al. EuroFlow antibody panels for standardized n‐dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75. PubMed PMC
Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A, O’Gorman MR. Clinical significance of isolated myeloperoxidase expression in pediatric B‐lymphoblastic leukemia. Am J Clin Pathol. 2017;147:374–81. PubMed
Savaşan S, Buck S, Gadgeel M, Gabali A. Flow cytometric false myeloperoxidase‐positive childhood B‐lineage acute lymphoblastic leukemia. Cytometry. 2018;94:477–83. PubMed
Porwit A, Béné MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. Cytometry. 2019;96:183–94. PubMed
Guy J, Antony‐Debré I, Benayoun E, Arnoux I, Fossat C, Le Garff‐Tavernier M, et al. Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. Br J Haematol. 2013;161:551–5. PubMed
van den Ancker W, Westers TM, de Leeuw DC, van der Veeken YF, Loonen A, van Beckhoven E, et al. A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry. 2013;84:114–8. PubMed
Saravanan L, Juneja S. Immunohistochemistry is a more sensitive marker for the detection of myeloperoxidase in acute myeloid leukemia compared with flow cytometry and cytochemistry. Int J Lab Hematol. 2010;32:e132–6. PubMed
Manivannan P, Puri V, Somasundaram V, Purohit A, Sharma RK, Dabas M, et al. Can threshold for MPO by flow cytometry be reduced in classifying acute leukaemia? A comparison of flow cytometric and cytochemical myeloperoxidase using different flow cytometric cut‐offs. Hematology. 2015;20:455–61. PubMed
Lee H, Kim Y, Kim YJ, Han K. An unusual case of myeloperoxidase‐positive acute megakaryoblastic leukemia. Ann Lab Med. 2015;35:466–8. PubMed PMC
